The ectopic expression of LMO1 or LMO2 in T cell acute leukaemias resulting from chromosomal translocations t(11;14)(p15;q11) or t(11;14)(p13;q11) respectively in a causal factor in tumorigenesis. LMO1 has been found as a heterodimer with a 46 Kd protein in a T cell line derived from a childhood T-acute leukaemia. This 46 Kd protein is the LIM-binding protein LDB1/NLI. The latter is a phosphoprotein and binds to LMO1 in its phosphorylated state and essentially all the LMO1 and LDB1 protein in the T cell line is part of the complex. Therefore, the LMO1-LDB1 interaction is likely to be involved in tumorigenesis after LMO1 is ectopically expressed following chromosomal translocation in T cells prior to development of acute leukaemias.
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The genes encoding the LMO1 and LMO2 proteins (previously known as RBTN1/TTG1 or RBTN2/ TTG2) were discovered as transcription units adjacent to the breakpoints of chromosomal translocations t(11;14)(p15;q11) (Boehm et al., 1988 (Boehm et al., , 1990a (Boehm et al., , 1991a McGuire et al., 1989) and t(11;14)(p13;q11) (Boehm et al., 1991a; Royer-Pokora et al., 1991) respectively. Both LMO1 and LMO2 proteins (as well as the other family member LMO3 (Boehm et al., 1991a; Foroni et al., 1992) ) are LIM-only proteins which have two zincbinding LIM domains, each comprising two LIM ®ngers. The chromosomal translocations activating LMO1 and LMO2 are found only in T cell tumours and it seems likely that ectopic expression of the LIMproteins contributes to leukaemogenesis by the ability to form aberrant protein associations in T cells (Rabbitts, 1994) . High mRNA and protein levels can be found in T cell lines derived from childhood T cell leukaemias with the relevant translocations (Boehm et al., 1991b; Foroni et al., 1992; Royer-Pokora et al., 1991) . Analysis of a T cell line with a t(11;14)(p15;q11), and expressing the LMO1 gene, showed that LMO1 interacts with at least two proteins in the nucleus of these cells; viz. TAL1/SCL and an uncharacterized 46 Kd protein (Valge-Archer et al., 1994) . The ability of the LIM domains of LMO1 and LMO2 to act as surfaces for protein interaction (Valge-Archer et al., 1994; Wadman et al., 1994) provides a function for these zinc-containing modules and data on LMO2-containing protein complexes in erythroid cells (Wadman et al., 1994) and in T cell tumours arising in transgenic mice (Grutz et al., 1998) suggest that protein interaction, but not direct DNA binding, is the speci®c function of the LIM-only proteins LMO1 and LMO2.
Current molecular models propose that aberrant T cell-associated protein complexes, brought together by the LMO proteins after ectopic expression, contribute to tumorigenesis. The nature of the 46 Kd protein to which LMO1 binds is relevant to this issue because it is present in a complex with LMO1 in human T cell acute leukaemia line carrying the translocation t(11;15)(p15;q11). Thus far, the identity of the 46 Kd protein has not been determined because it is obscured by the similarity in its molecular weight of TAL1, which also binds LMO1 (Valge-Archer et al., 1994) . A candidate for the 46 Kd protein is the recently identi®ed LIM-binding protein LDB1 or NLI (Agulnick et al., 1996; Jurata et al., 1996) (herein called LDB1). This protein has been shown to interact in vitro with LMO1 and LMO2 (Agulnick et al., 1996; Jurata et al., 1996) and in vivo LMO2 has been found in complexes with LDB1 in erythroid cells (Wadman et al., 1997) and in T cells from Lmo2-transgenic mice (Grutz et al., 1998) . We have assessed the interaction of LMO1 and LDB1 in the human T cell acute leukaemia cell line RPMI8402 (which has been t(11;14)(p15;q11)) using a two-step immunoprecipitation protocol described previously (Valge-Archer et al., 1994) . The T cells were labelled with 35 S-methionine/ cysteine and labelled proteins immunoprecipitated with a rabbit antiserum raised with an LMO1-speci®c peptide. The precipitated proteins were subsequently analysed by fractionation on SDS ± PAGE (Figure 1a ). This procedure precipitates the 18 Kd LMO1 protein as well as the 46 Kd protein (lane 1), together with some higher molecular weight proteins (which are non-speci®c since the pre-immune serum from the animal used for peptide immunization, also precipitated these bands, lane 3). Using an anti-LDB1 serum, a similar pro®le of immunoprecipitated proteins appears, notably the 18 Kd band which is most likely to be LMO1 (lane 5) since it is not evident with LDB1 pre-immune serum (lane 8). When the immunoprecipitated proteins obtained with anti-LMO1 serum were resuspended and re-immunoprecipitated with anti-LDB1 serum, we observed the speci®c immunoprecipitation of LDB1, which co-migrates with the 46 Kd protein (lane 2). In a reciprocal experiment, anti-LMO1 immunoprecipitation of the anti-LDB1 immunoprecipitate showed the LMO1 18 Kd protein (lane 6). Thus the 46 Kd LMO1-interacting protein is the LIM-binding protein LDB1.
Con®rmation of the association of LMO1 with the LDB1 protein was obtained by immunoprecipitating LMO1 in the presence of the peptide used to raise the LMO1 antiserum. In this analysis, no speci®c LMO1 or 46 Kd proteins were immunoprecipitated (lane 3). In addition, using the two-step immunoprecipitation procedure, when the LDB1 immune precipitate was reprecipitated by anti-LMO1 serum in the presence of LMO1 peptide, the 18 Kd protein did not appear (lane 7), demonstrating that this protein is indeed LMO1. Estimations of the amounts of LMO1 and LDB1 proteins in a complex with each other can be made by comparing amounts of radioactivity in each precipitated band. Thus it appears that almost all LMO1 protein is complexed with LDB1 in the T-ALL cell line since the same amount of radiolabelled LMO1 is observed in immunoprecipitations with either anti-LMO1 and anti-LDB1 sera (Figure 1, lanes 1 and 5) . Similarly, most of the LDB1 protein is co-precipitated with LMO1 with either antiserum.
In an analysis of Lmo1 gene expression in mouse tissues and cells, it was observed that Lmo1 is expressed in some neuroblastomas (Boehm et al., 1990b (Boehm et al., , 1991b Greenberg et al., 1990; McGuire et al., 1991) . These are neurogenic tumours which arise from nerve cells of the sympathetic nervous system, which may include cells normally expressing Lmo1 (Boehm et al., 1991b; Greenberg et al., 1990; McGuire et al., 1991) . Thus neuroblastomas may represent a normal cell type in which to examine Lmo1-Ldb1 interaction. Accordingly, the mouse neuroblastoma cell line 131-CCL (N2A), which expresses Lmo1 (Boehm et al., 1991b) , was incubated with [ 35 S]methionine/cysteine for immunoprecipitation studies (Figure 1b) . This cell line expresses low levels of Lmo1 protein (lanes 1 and 3) but nonetheless anti-Lmo1 antiserum co-precipitates a 46 Kd protein (lanes 1 and 5) . The immunoprecipitation of these proteins can be blocked by incubation with the Lmo1 peptide (lane 3). The identity of this as Ldb1 was con®rmed by the two-step immunoprecipitation method (lane 2) or by peptide blocking in the second precipitation step (lane 7).
Previous analyses of LMO1 showed that this protein was not normally phosphorylated in vivo in RPMI8402 cells (Valge-Archer et al., 1994) . The possibility that LDB1 might be a phosphoprotein was investigated. RPMI8402 cells were radiolabelled with 33 P i and immunoprecipitation carried out (Figure 2 ). LDB1 is S-cysteine. Total cellular proteins from RPMI8402 T cell acute leukaemia cells (a) or N2A (131-CCL) neuroblastoma cells (b) were immunoprecipitated with the indicated antisera. In the case of two-step immunoprecipitation, the ®rst antiserum is indicated followed by an arrow and the second antiserum. Each lane 3 is a two-step immunoprecipitation carried out with pre-immune serum used for the second step. LMO1+peptide indicates an immunoprecipitation carried with anti-LMO1 antiserum in the presence of 50-fold excess of the immunizing peptide. In one case for each panel, the second LMO1 immunoprecipitation was carried out with blocking LMO1 peptide. pi indicates pre-immune serum from the LMO1 antiserum. Commercially available size markers were used to estimate size in Kd, as shown between panels. Methods: Cells were grown to mid-log phase, labelled for 4 h at about 2610 7 cells/ml, in the presence of 200 mCi S-methionine. Protein extracts were prepared as previously described (Valge-Archer et al., 1994) and one-and two-step immunoprecipitations carried out with N-terminal anti-peptide anti-LMO1 antiserum (Valge-Archer et al., 1994) . Peptide blocking was carried out by pre-incubating the serum with peptide for 1 h prior to immunoprecipitation. The rabbit polyclonal antiserum was raised against an NH 2 -terminal peptide of LMO. Rabbit antiserum for Ldb1 has been described (Wadman et al., 1997) (note the sequence of mouse Ldb1 and human LDB1 are identical in the region of the peptide) phosphorylated in these cells, as the 46 Kd protein is precipitated with the anti-LDB1 serum (lane 1) but not by the pre-immune serum (lane 2). Further, anti-LMO1 serum also precipitates the 46 Kd LDB1 protein (lane 3) but no LMO1 protein is evident (as it is not phosphorylated). Finally, the LDB1 phospho-protein can be found in complex with LMO1 by the two-step protocol (lane 4) and this co-precipitation is blocked by LMO1 peptide (lane 5).
Our results provide further formal proof that endogenous LDB1 protein interacts with LIM-only proteins, in this case LMO1. The functional significance of this heterodimerization is unclear but at least some of this complex must also involve TAL1 as this also co-precipitates with LMO1 in RPMI8402 cells (Valge-Archer et al., 1994) , although a relatively small amount appears to be part of the complex. One potential function for the Lmo1-related protein Lmo2 is in the formation or maintenance of a complex of proteins capable of binding to distinct bipartite DNA recognition sites in erythroid cells and in transgenic T cells tumours after enforced Lmo2 expression in thymus cells (Grutz et al., 1998; Wadman et al., 1997) . Thus ectopic LMO1 expression may similarly cause aberrant T cell complexes to form, including heterodimerization between LMO1 and LDB1. At present evidence for the existence of an LMO1-containing oligomeric complex, which would be the analogue of those found with Lmo2, is restricted to data with LDB1 and TAL1. Other proteins may also be present in the LMO1 complex. Whether LMO1 functions in the development of T-ALL by facilitating the formation of a DNA binding complex or by sequestration of components within this complex preventing their function (Grutz et al., 1998) , the involvement of protein-protein interactions not usually found in T cells presumably accounts for the pathogenic eects of the t(11;14)(p15;q11), underscoring the importance of protein interactions in the modes of action of translocation-activated oncogenes.
